



## Clinical and genetic study of ataxia with vitamin E deficiency: A case report

Lin-Wei Zhang, Bing Liu, Dan-Tao Peng

**Specialty type:** Clinical neurology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Greco T, Italy; Kumar S, India

**Received:** January 20, 2022

**Peer-review started:** January 20, 2022

**First decision:** May 11, 2022

**Revised:** May 23, 2022

**Accepted:** July 11, 2022

**Article in press:** July 11, 2022

**Published online:** August 16, 2022



**Lin-Wei Zhang, Dan-Tao Peng,** Department of Neurology, China-Japan Friendship Hospital, Beijing 100029, China

**Bing Liu,** Department of Radiology, China-Japan Friendship Hospital, Beijing 100029, China

**Corresponding author:** Dan-Tao Peng, MD, Chief Doctor, Department of Neurology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing 100029, China. [pengdt2000@126.com](mailto:pengdt2000@126.com)

### Abstract

#### BACKGROUND

Ataxia with vitamin E deficiency (AVED) is a type of autosomal recessive cerebellar ataxia. Clinical manifestations include progressive cerebellar ataxia and movement disorders. *TTPA* gene mutations cause the disease.

#### CASE SUMMARY

We report the case of a 32-year-old woman who presented with progressive cerebellar ataxia, dysarthria, dystonic tremors and a remarkably decreased serum vitamin E concentration. Brain magnetic resonance images showed that her brainstem and cerebellum were within normal limits. Acquired causes of ataxia were excluded. Whole exome sequencing subsequently identified a novel homozygous variant (c.473T>C, p.F158S) of the *TTPA* gene. Bioinformatic analysis predicted that F158S is harmful to protein function. After supplementing the patient with vitamin E 400 mg three times per day for 2 years, her symptoms remained stable.

#### CONCLUSION

We identified an AVED patient caused by novel mutation in *TTPA* gene. Our findings widen the known *TTPA* gene mutation spectrum.

**Key Words:** Ataxia with vitamin E deficiency; *TTPA* gene; Tremor; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Ataxia with vitamin E deficiency can present as progressive chronic cerebellar ataxia and involuntary movement disorder. Vitamin E supplementation should be initiated as early as possible to stop disease progression.

**Citation:** Zhang LW, Liu B, Peng DT. Clinical and genetic study of ataxia with vitamin E deficiency: A case report. *World J Clin Cases* 2022; 10(23): 8271-8276

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i23/8271.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v10.i23.8271>

## INTRODUCTION

Ataxia with vitamin E deficiency (AVED) is a type of autosomal recessive cerebellar ataxia (ARCA). The most prominent symptoms include cerebellar ataxia, areflexia, peripheral neuropathy and movement disorder[1,2]. AVED patients may also exhibit retinitis pigmentosa, cardiomyopathy and scoliosis[3,4]. AVED is caused by mutations in the *TTPA* gene, which encodes the  $\alpha$ -tocopherol transfer protein, which in turn binds  $\alpha$ -tocopherol and transports vitamin E from hepatocytes to circulating lipoproteins[5]. Vitamin E supplementation may prevent the worsening of the condition of patients with AVED.

To date, the known incidence rate of AVED in China has been low[6]. Here, we report the clinical, biochemical and genetic investigation of a Chinese patient with AVED due to homozygous mutations in the *TTPA* gene. This patient exhibited progressive cerebellar ataxia, dysarthria and head titubation with markedly low levels of serum vitamin E. After treatment with vitamin E 400 mg three times per day for 2 years, the patient's neurological symptoms were stabilized.

## CASE PRESENTATION

### Chief complaints

A 32-year-old woman was admitted to the hospital because of progressive cerebellar ataxia and involuntary head tremors.

### History of present illness

When the patient was 14-years-old, she began exhibiting an unsteady gait which worsened to become wide-based and staggering. She also developed slurring of speech and clumsiness of the hands. At 18 years of age, she began having involuntary dystonic head tremors as well.

### History of past illness

She had no specific intestinal lesions indicative of malabsorption. Past medical history was unremarkable.

### Personal and family history

Her parents are cousins. There is no family history of similar neurological disorders.

### Physical examination

Neurological examination revealed normal cognitive state, dysarthria, overt head tremor, bilateral dysmetria on nose-finger and heel-shin tests and a wide-based ataxic gait with inability to walk in tandem. Kayser-Fleischer Rings were absent; vision and hearing ability were normal. Motor and sensory examinations yielded normal results apart from areflexia. Romberg's sign and bilateral Babinski sign were positive; Pes cavus deformity noted. Obvious overt head dystonic tremor, bilateral dysmetria on finger-to-nose and heel-to-shin tests and wide-based gait with inability to walk in tandem. Scale for the assessment and rating of ataxia (SARA) score was 11 [gait 2, stance 2, sitting 0, speech 1, finger chase 1.0 (left 1, right 1), nose-finger test 2.0 (left 2, right 2), fast alternating hand movements 1.0 (left 1, right 1), and heel-shin slide 2.0 (left 2, right 2)].

### Laboratory examinations

Routine blood tests, including liver function, autoimmune antibodies, thyroid function, blood smear for acanthocytosis and plasma levels of vitamins (B1, B2, B6, B9, B12, A, D, E), copper and ceruloplasmin were normal. Cerebrospinal fluid was normal including inflammatory, immunological and infectious indices. Electromyography, nerve conduction velocity and brainstem auditory evoked potential were all normal. Initial DNA analyses using capillary electrophoresis of polymerase chain reaction products excluded Friedrich's ataxia, spinocerebellar ataxia (1, 2, 3, 6, 7, 8, 10, 12, 17) and dentatorubral-pallid-

olusian atrophy. The plasma level of total vitamin E detected *via* high performance liquid chromatography was 0.59 µg/mL (normal: 10.8 ± 3.3 mg/L[7]).

### Imaging examinations

Brain magnetic resonance imaging (MRI) showed no obvious atrophy of brainstem and cerebellum (Figure 1).

### Further diagnostic work-up

Genomic DNA was extracted from peripheral leukocytes of the patient and all available family members who gave written informed consent, according to the standard protocol approved by the China-Japan Friendship Hospital. DNA of the proband was subjected to whole exome sequencing (WES) using the Ion Torrent AmpliSeq Exome RDY kit (BGI Tech, Hong Kong). Variant call files were analyzed with Ingenuity Variant Analysis (Qiagen, Redwood City, CA, United States) using an autosomal recessive model. Clean reads were aligned on the human assembly GRCh37 by Burrow-Wheeler aligner. Small insertions/deletions and single nucleotide variants were called by genomic analysis toolkit and annotated by ANNOVAR. Several filtration steps to obtain putative pathogenic variants were processed. The functional effects of protein variants were predicted by Sorting Intolerant from Tolerant (SIFT), PolyPhen2 and MutationTaster. Disease association databases (*e.g.*, HGMD, OMIM and ClinVar) and genetic variation databases (*e.g.*, 1000 Genomes Project, ESP6500 and ExAC) were used in the filtering process as well. Potential pathogenic variants were validated by conventional Sanger sequencing and her family members were included for segregation analysis. We used the transcript sequence (OMIM\*600415, NM\_000370.3) of the *TTPA* gene and discovered homozygous variants(c.473C>T, p.Phe185Ser) in the proband. Sanger sequencing confirmed this result and revealed that her parents and the younger sister are heterozygous carriers for 473C>T (Figure 2). This mutation was predicted to be harmful (SIFT: tolerated, Polyphen2: possibly damaging, MutationTaster: disease causing). The 158-phenylalanine residue affected by the mutation were highly conserved in evolution (Figure 3).

## FINAL DIAGNOSIS

The final diagnosis of the presented case was AVED due to *TTPA* homozygous missense mutation (c.473C>T, p.Phe185Ser) (GRCh37/hg19).

## TREATMENT


After we detected decreased plasma levels of total vitamin E, supplementation with vitamin E 400 mg three times per day was immediately administered. The patient also kept physical exercises for rehabilitation therapy.

## OUTCOME AND FOLLOW-UP

After 2 years of vitamin E supplementation therapy, the symptoms of this patient showed neither improvement nor deterioration. On her last follow-up visit, her SARA score was 11 [gait 2, stance 2, sitting 0, speech 1, finger chase 1.5 (left 2, right 1), nose-finger test 1.5 (left 2, right 1), fast alternating hand movements 1.0 (left 1, right 1) and heel-shin slide 2.0 (left 2, right 2)].

## DISCUSSION


By WES we identified homozygous mutations of *TTPA* gene (c.473C>T, p.Phe185Ser) in a Chinese family with ARCA and we have excluded common causes of ataxia. AVED was first reported by Burck *et al*[8]. It usually manifests as a mild disease course and is rarely reported in China. The presentation of AVED is highly heterogeneous with onset usually in childhood[9] but some cases have manifested in infancy and in adulthood[1]. Clinical phenotypes include progressive gait ataxia, movement disorders, areflexia, dysarthria, epilepsy, pyramidal signs, impaired proprioception and vibration sense and sensory neuropathy[9-11]. Apart from cerebellar ataxia, our patient exhibited obvious head tremor. Head titubation, seen in 37% to 73% of patients, and cervical dystonia are distinguishing motor features of AVED[1,3,12]. Non-neurological symptoms, such as retinitis pigmentosa, macular degeneration and cardiomyopathy[13,14] were not found in our patient. Laboratory examination often reveals markedly low serum vitamin E concentration in AVED[1]. The patient's MRI showed no obvious cerebellar



**Figure 1** Pedigree and sanger sequencing validation of homozygous mutation c.473T>C, p.F158S of *TTPA* gene in this pedigree. Clear square: Male; Clear circle: Female; Black circle: Index patient.



**Figure 2** Brain magnetic resonance images show relatively normal brainstem and cerebellum of the index patient (II:1).



**Figure 3** Evaluation of the mutation p.Arg301Gln is highly conserved among species.

atrophy in our patient and absence of cerebellar atrophy is common in AVED patients[15]. To date, various mutations of the *TTPA* gene have been reported[16]. The genotype-phenotype correlations were not found to be strong in AVED and c.744delA was the most frequent mutation, often originating in the Mediterranean region[9]. Moreover, 744delA could increase the risk of early age onset, severe disease course and cardiomyopathy[17]. c.473C>T(p.F158S), which was detected in our patient, has not been reported previously. Her symptoms began in adolescence and she is still able to walk 18 years after the onset of disease. F158S is located in CRAL\_TRIO domain and its predicted function is to

combine with  $\alpha$ -tocopherol[18]. Bioinformatic analysis predicted this novel mutation would lead to the damage of protein function.

AVED is a treatable form of hereditary ataxia and early and sustained vitamin E supplementation could result in a remarkable clinical response or stabilization in AVED patients[1,19,20]. In patients with ataxia, a prompt investigation for vitamin E deficiency is recommended[19,20]. AVED patients require lifelong vitamin E supplementation at 300-2400 mg/d to maintain adequate plasma levels of vitamin E [1,8,14]. Our patient received 1200 mg/d of vitamin E for 2 years and her symptoms showed no deterioration.

## CONCLUSION

We identified a Chinese AVED female patient caused by a novel mutation in the *TTPA* gene. This finding widens the known *TTPA* gene mutation spectrum.

## ACKNOWLEDGEMENTS

We thank the patient who participated in our study and her family members.

## FOOTNOTES

**Author contributions:** Zhang LW contributed to acquisition of data, carried out the molecular genetic studies, analyzed the molecular and clinical data, wrote the main manuscript text and prepared figures; Liu B collected data during the study; Peng DT critically revised the manuscript for important intellectual content and supervised the study; All authors read and approved the manuscript.

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Lin-Wei Zhang 0000-0002-7094-8345; Bing Liu 0000-0002-3938-1539; Dan-Tao Peng 0000-0001-8038-3192.

**S-Editor:** Gong ZM

**L-Editor:** Filipodia

**P-Editor:** Gong ZM

## REFERENCES

- 1 **El Euch-Fayache G**, Bouhail Y, Amouri R, Feki M, Hentati F. Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency. *Brain* 2014; **137**: 402-410 [PMID: 24369383 DOI: 10.1093/brain/awt339]
- 2 **Hamza W**, Ali Pacha L, Hamadouche T, Muller J, Drouot N, Ferrat F, Makri S, Chaouch M, Tazir M, Koenig M, Benhassine T. Molecular and clinical study of a cohort of 110 Algerian patients with autosomal recessive ataxia. *BMC Med Genet* 2015; **16**: 36 [PMID: 26068213 DOI: 10.1186/s12881-015-0180-3]
- 3 **Benomar A**, Yahyaoui M, Meggouh F, Bouhouche A, Boutchich M, Bouslam N, Zaim A, Schmitt M, Belaidi H, Ouazzani R, Chkili T, Koenig M. Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. *J Neurol Sci* 2002; **198**: 25-29 [PMID: 12039660 DOI: 10.1016/s0022-510x(02)00057-6]
- 4 **Esmer C**, Salazar MA, Rentería PE, Bravo OA. Clinical and molecular findings in a patient with ataxia with vitamin E deficiency, homozygous for the c.205-1G>C mutation in the *TTPA* gene. *Bol Med Hos Infant Mex* 2013; **70**: 313-317



- 5 **Chung S**, Ghelfi M, Atkinson J, Parker R, Qian J, Carlin C, Manor D. Vitamin E and Phosphoinositides Regulate the Intracellular Localization of the Hepatic  $\alpha$ -Tocopherol Transfer Protein. *J Biol Chem* 2016; **291**: 17028-17039 [PMID: 27307040 DOI: 10.1074/jbc.M116.734210]
- 6 **Hao Y**, Gu W, Wang G, Chen Y, Zhang J. Clinical and genetic study of ataxia with isolated vitamin E deficiency. *Zhonghua Shenjingke Zazhi* 2014; **47**: 90-95 [DOI: 10.3760/cma.j.issn.1006-7876.2014.02.005]
- 7 **Kono S**, Otsuji A, Hattori H, Shirakawa K, Suzuki H, Miyajima H. Ataxia with vitamin E deficiency with a mutation in a phospholipid transfer protein gene. *J Neurol* 2009; **256**: 1180-1181 [PMID: 19252769 DOI: 10.1007/s00415-009-5075-9]
- 8 **Burck U**, Goebel HH, Kuhlendahl HD, Meier C, Goebel KM. Neuromyopathy and vitamin E deficiency in man. *Neuropediatrics* 1981; **12**: 267-278 [PMID: 6945489 DOI: 10.1055/s-2008-1059657]
- 9 **Elkamil A**, Johansen KK, Aasly J. Ataxia with vitamin e deficiency in norway. *J Mov Disord* 2015; **8**: 33-36 [PMID: 25614784 DOI: 10.14802/jmd.14030]
- 10 **Pearson TS**. More Than Ataxia: Hyperkinetic Movement Disorders in Childhood Autosomal Recessive Ataxia Syndromes. *Tremor Other Hyperkinet Mov (N Y)* 2016; **6**: 368 [PMID: 27536460 DOI: 10.7916/D8H70FSS]
- 11 **Müller KI**, Bekkelund SI. Epilepsy in a patient with ataxia caused by vitamin E deficiency. *BMJ Case Rep* 2011; **2011** [PMID: 22696689 DOI: 10.1136/bcr.01.2011.3728]
- 12 **Becker AE**, Vargas W, Pearson TS. Ataxia with Vitamin E Deficiency May Present with Cervical Dystonia. *Tremor Other Hyperkinet Mov (N Y)* 2016; **6**: 374 [PMID: 27274910 DOI: 10.7916/D8B85820]
- 13 **Iwasa K**, Shima K, Komai K, Nishida Y, Yokota T, Yamada M. Retinitis pigmentosa and macular degeneration in a patient with ataxia with isolated vitamin E deficiency with a novel c.717 del C mutation in the TTPA gene. *J Neurol Sci* 2014; **345**: 228-230 [PMID: 25066259 DOI: 10.1016/j.jns.2014.07.001]
- 14 **Mariotti C**, Gellera C, Rimoldi M, Mineri R, Uziel G, Zorzi G, Pareyson D, Piccolo G, Gambi D, Piacentini S, Squitieri F, Capra R, Castellotti B, Di Donato S. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. *Neurol Sci* 2004; **25**: 130-137 [PMID: 15300460 DOI: 10.1007/s10072-004-0246-z]
- 15 **Fogel BL**, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. *Lancet Neurol* 2007; **6**: 245-257 [PMID: 17303531 DOI: 10.1016/S1474-4422(07)70054-6]
- 16 **Di Donato I**, Bianchi S, Federico A. Ataxia with vitamin E deficiency: update of molecular diagnosis. *Neurol Sci* 2010; **31**: 511-515 [PMID: 20464573 DOI: 10.1007/s10072-010-0261-1]
- 17 **Marzouki N**, Benomar A, Yahyaoui M, Birouk N, Elouazzani M, Chkili T, Benlemlih M. Vitamin E deficiency ataxia with (744 del A) mutation on alpha-TTP gene: genetic and clinical peculiarities in Moroccan patients. *Eur J Med Genet* 2005; **48**: 21-28 [PMID: 15953402 DOI: 10.1016/j.ejmg.2005.01.014]
- 18 **Min KC**, Kovall RA, Hendrickson WA. Crystal structure of human alpha-tocopherol transfer protein bound to its ligand: implications for ataxia with vitamin E deficiency. *Proc Natl Acad Sci USA* 2003; **100**: 14713-14718 [PMID: 14657365 DOI: 10.1073/pnas.2136684100]
- 19 **Kohlschütter A**, Finckh B, Nickel M, Bley A, Hübner C. First Recognized Patient with Genetic Vitamin E Deficiency Stable after 36 Years of Controlled Supplement Therapy. *Neurodegener Dis* 2020; **20**: 35-38 [PMID: 32623435 DOI: 10.1159/000508080]
- 20 **Schuelke M**, Mayatepek E, Inter M, Becker M, Pfeiffer E, Speer A, Hübner C, Finckh B. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. *J Pediatr* 1999; **134**: 240-244 [PMID: 9931538 DOI: 10.1016/s0022-3476(99)70424-5]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

